Sarcoma Unit News Today

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.

The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.

Ukrainian doctors are receiving further training at seven hospitals in Germany. The BG University Hospital Bergmannsheil Bochum specializes in treating serious injuries and burns, particularly those of soldiers.

Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors - read this article along with other careers information, tips and advice on BioSpace

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Nirogacestat showed improved progression-free survival, pain scores, symptoms, and quality of life in patients with progressive desmoid tumors in a phase 3 trial hailed as practice changing.